{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-024744","form_type":"8-K","ticker":"CRDF","cik":"0001213037","company_name":"Cardiff Oncology, Inc.","filed_at":"2022-09-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.158137+00:00","generated_at":"2026-06-23T10:46:44.618488+00:00","sec_items":["8.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Cardiff Oncology plans randomized Phase 2 mCRC trial (ONSEMBLE) with topline data in 2H 2024; cash runway into 2025","bullets":["Phase 1b/2 mCRC data show ORR 35%, mPFS 9.3 mo, median DoR 11.7 mo; historical controls ORR 5-13%, mPFS 4.5-5.7 mo.","ONSEMBLE trial to enroll ~150 patients randomized 1:1:1 to SoC ± 20/30 mg onvansertib; primary endpoint ORR.","Phase 2 PDAC trial: 1 PR, 3 SD in 5 evaluable patients; additional data expected Q2/Q3 2023.","Company stops independent funding of prostate cancer program; will focus on mCRC and PDAC.","Cash resources expected to fund operations into 2025; investigator-initiated trials in TNBC and SCLC ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-024744","json":"https://secwatch.observer/filing/0001628280-22-024744.json","markdown":"https://secwatch.observer/filing/0001628280-22-024744.md","text":"https://secwatch.observer/filing/0001628280-22-024744.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213037/000162828022024744/0001628280-22-024744-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213037/000162828022024744/crdf-20220910.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T10:46:44.618488+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}